MARC details
| 000 -CABECERA |
|---|
| campo de control de longitud fija |
06770cam a2200469 i 4500 |
| 001 - NÚMERO DE CONTROL |
|---|
| campo de control |
991107524761506196 |
| 005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN |
|---|
| campo de control |
20260128114339.0 |
| 008 - DATOS DE LONGITUD FIJA--INFORMACIÓN GENERAL |
|---|
| campo de control de longitud fija |
250221t20252025nyu b 001 0 eng d |
| 010 ## - NÚMERO DE CONTROL DE LA BIBLIOTECA DEL CONGRESO |
|---|
| Número de control de LC |
2024005973 |
| 020 ## - NÚMERO INTERNACIONAL ESTÁNDAR DEL LIBRO |
|---|
| Número Internacional Estándar del Libro |
9780593229866 |
| Información calificativa |
(hardcover) |
| 035 ## - NÚMERO DE CONTROL DEL SISTEMA |
|---|
| Número de control de sistema |
(OCoLC)1505528503 |
| 035 ## - NÚMERO DE CONTROL DEL SISTEMA |
|---|
| Número de control de sistema |
(OCoLC)on1505528503 |
| 040 ## - FUENTE DE LA CATALOGACIÓN |
|---|
| Centro catalogador/agencia de origen |
LMJ |
| Lengua de catalogación |
eng |
| Normas de descripción |
rda |
| Centro/agencia transcriptor |
LMJ |
| Centro/agencia modificador |
FLW |
| -- |
IG# |
| -- |
OCLCO |
| -- |
CCPLG |
| -- |
OCO |
| -- |
OJ4 |
| -- |
IMD |
| -- |
MJ8 |
| -- |
IMT |
| -- |
OCLCO |
| -- |
WIM |
| -- |
JRX |
| -- |
OCLCO |
| -- |
IUK |
| -- |
OCLCA |
| -- |
GO4 |
| -- |
CLE |
| -- |
WKM |
| -- |
CQC |
| -- |
UNB |
| -- |
HMS |
| -- |
OCLCO |
| -- |
Y#4 |
| -- |
OCLCO |
| -- |
PAU |
| -- |
P4Q |
| -- |
TSC |
| -- |
OCLCO |
| 041 ## - CÓDIGO DE LENGUA |
|---|
| Código de lengua del texto/banda sonora o título independiente |
EN |
| 043 ## - CÓDIGO DE ÁREA GEOGRÁFICA |
|---|
| Código de área geográfica |
n-us--- |
| 050 04 - SIGNATURA TOPOGRÁFICA DE LA BIBLIOTECA DEL CONGRESO |
|---|
| Número de clasificación |
HD9666.9.J6 |
| Número de documento/Ítem |
H37 2025 |
| 100 ## - ENTRADA PRINCIPAL--NOMBRE DE PERSONA |
|---|
| Nombre de persona |
Harris, Gardiner, |
| Término indicativo de función/relación |
author. |
| URI de un objeto del mundo real |
https://id.oclc.org/worldcat/entity/E39PCjtrkYfFBV8tKpHY8pd8yb |
| 9 (RLIN) |
26686 |
| 245 10 - MENCIÓN DE TÍTULO |
|---|
| Título |
No more tears |
| Resto del título |
: the dark secrets of Johnson & Johnson |
| Mención de responsabilidad, etc. |
/ Gardiner Harris. |
| 246 30 - FORMA VARIANTE DE TÍTULO |
|---|
| Título propio/Titulo breve |
Dark secrets of Johnson & Johnson |
| 250 ## - MENCIÓN DE EDICIÓN |
|---|
| Mención de edición |
First edition. |
| 264 #1 - PRODUCCIÓN, PUBLICACIÓN, DISTRIBUCIÓN, FABRICACIÓN Y COPYRIGHT |
|---|
| Producción, publicación, distribución, fabricación y copyright |
New York : |
| Nombre del de productor, editor, distribuidor, fabricante |
Random House |
| Fecha de producción, publicación, distribución, fabricación o copyright |
[2025] |
| 300 ## - DESCRIPCIÓN FÍSICA |
|---|
| Extensión |
xviii, 444 pages ; |
| Dimensiones |
25 cm |
| 500 ## - NOTA GENERAL |
|---|
| Nota general |
"Deception corruption death" -- Cover. |
| 504 ## - NOTA DE BIBLIOGRAFÍA, ETC. |
|---|
| Nota de bibliografía, etc. |
Includes bibliographical references (pages 357-428) and index. |
| 505 0# - NOTA DE CONTENIDO CON FORMATO |
|---|
| Nota de contenido con formato |
Introduction: A quintessentially American company — Part I: Consumer products. Section I: Trust from birth. An emotional bond — Three brothers go to New Brunswick, 1860-1968 — Section II: Johnson's baby powder. Mineral twins — The FDA conducts a survey — Birth of the modern FDA — The power of pressure — A meeting at a Harvard hospital — Secrecy is a top priority — A sacred cow — Section III: Tylenol. An infamous crime, the birth of a myth — Problems with the narrative — Never an adversarial relationship — The cost of doing business — Part II: Prescription drugs. A valley of death in drug discovery — Section IV: Procrit. The first great biotech franchise is born — How giving cash to doctors became good business — J & J's biggest-selling drug — A brave researcher breaks the silence — Miracle-Gro for cancer — Section V: Risperdal. A path of a normal life — A treatment for everything and everyone — Serious red flags — A big target — Ice cream and popcorn parties — A turning point — One of the most alarming warnings — They knew they were a good company — Section VI: Duragesic. An epidemic foretold — Opium blossoms in Tasmania — Less prone to abuse — Evolve the value discussion — Section VII: Ortho Evra birth control patch. The pill and the patch — Part III: Medical devices. The FDA goes looking for a savior — Section VIII: Pinnacle metal-on-metal hip implant. Two terrible dilemmas — God, Nazis, and hip implants — Never stop moving — Section IX: Prolift vaginal mesh. A cure for sag — "Usually minor and well manageable" — Part VI: Vaccination. Section X: COVID. A rare shot a redemption. |
| 520 ## - SUMARIO, ETC. |
|---|
| Sumario, etc. |
"When reporter Gardiner Harris met a woman at an airport bar whose entire family has been shattered by her nephew's use of the drug Risperdal, one she sold to his doctor as a drug sales rep, he began to wonder how many similar stories are out there. This was in 2004, and since then, Harris has been investigating one of the largest players in Big Pharma, continuously reporting on it despite simultaneous landmark journalistic accomplishments, like exposing the extremely toxic mining conditions ignored by coal companies. For decades, pharmaceutical giant Johnson & Johnson was seen as a paragon of ethical conduct, especially considering the company's child-friendly products like baby powder and tearless shampoo. However, Harris has uncovered reams of evidence of deceitful and dangerous corporate practices that reveal a historic threat to the health of the American public. He covers several disasters: tissue death caused by J & J's touted hip replacements, their coverup of baby powder's linkage to cancer, the teen-directed marketing of the life-altering drug Risperdal, and more. The Hatch-Waxman Bill, which is meant to pave the way for lower-priced generic drugs, passed in 1984, and inadvertently created loopholes in the drug approval process which allowed urgency and profit maximization to take precedence over diligence and patient protection. Johnson & Johnson's subsequent lack of oversight, money-grubbing, and flat out lies have resulted in the death or serious injury of millions of people. To many, the peril of falsified science seems distant, but Harris reveals how a combination of misrepresented data and bribe culture directly impact doctors' decisions -- which are devastatingly revealed to be not at all in the interests of patients."-- |
| Fuente proveedora |
Provided by publisher. |
| 520 ## - SUMARIO, ETC. |
|---|
| Sumario, etc. |
No More Tears is a hard-hitting work of investigative journalism that exposes the darker side of Johnson & Johnson, one of America’s oldest and most trusted healthcare companies. Written by New York Times reporter Gardiner Harris, the book traces decades of corporate misconduct hidden behind the company’s carefully cultivated image as a safe, family-friendly “baby company”.<br/><br/>The story begins in 2004, when Harris meets a Johnson & Johnson sales representative by chance at an airport bar. Her account of unethical sales practices and the damage they caused to her own family becomes the catalyst for years of reporting that ultimately lead to this book.<br/><br/>Harris documents how the company repeatedly put profits before patients, covering up risks and aggressively marketing dangerous products. He examines scandals involving Johnson’s Baby Powder and its links to cancer, the underestimated dangers of Tylenol, the illegal promotion of antipsychotic drugs, cancer treatments that may have worsened tumour growth, and the role of the fentanyl patch Duragesic in fuelling the opioid crisis.<br/><br/>Through detailed reporting and insider testimony, the book reveals a pattern of deception, regulatory pressure, and calculated risk-taking that endangered millions of lives. No More Tears dismantles the comforting public image of Johnson & Johnson and presents a troubling portrait of a healthcare giant whose actions often betrayed the trust placed in it. |
| 610 20 - PUNTO DE ACCESO ADICIONAL DE MATERIA--NOMBRE DE ENTIDAD CORPORATIVA |
|---|
| Nombre de entidad corporativa o nombre de jurisdicción como elemento de entrada |
Johnson & Johnson. |
| 9 (RLIN) |
26687 |
| 610 #0 - PUNTO DE ACCESO ADICIONAL DE MATERIA--NOMBRE DE ENTIDAD CORPORATIVA |
|---|
| Nombre de entidad corporativa o nombre de jurisdicción como elemento de entrada |
Johnson & Johnson. |
| 9 (RLIN) |
26687 |
| 650 #0 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Pharmaceutical industry |
| Subdivisión general |
Corrupt practices United States. |
| Subdivisión geográfica |
United States. |
| 650 #0 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Pharmaceutical industry |
| Subdivisión general |
Moral and ethical aspects. |
| 9 (RLIN) |
26689 |
| 650 #0 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Medical care |
| Subdivisión general |
Corrupt practices United States. |
| Subdivisión geográfica |
United States. |
| 650 #0 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Medical ethics. |
| 650 10 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Drug Industry |
| Subdivisión general |
ethics |
| 9 (RLIN) |
26691 |
| 650 12 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Delivery of Health Care |
| Subdivisión general |
ethics |
| 650 10 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Professional Misconduct |
| 9 (RLIN) |
26692 |
| 650 20 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Ethics, Medical |
| 9 (RLIN) |
26693 |
| 650 20 - PUNTO DE ACCESO ADICIONAL DE MATERIA--TÉRMINO DE MATERIA |
|---|
| Término de materia o nombre geográfico como elemento de entrada |
Business ethics |
| 9 (RLIN) |
3022 |
| 651 #0 - PUNTO DE ACCESO ADICIONAL DE MATERIA--NOMBRE GEOGRÁFICO |
|---|
| Nombre geográfico |
United States |
| 9 (RLIN) |
22762 |
| 655 #0 - TÉRMINO DE INDIZACIÓN--GÉNERO/FORMA |
|---|
| Datos o término principal de género/forma |
Informational works |
| Fuente del término |
lcgft |
| 9 (RLIN) |
23310 |
| 942 ## - ELEMENTOS DE ENTRADA AGREGADA (KOHA) |
|---|
| Fuente del sistema de clasificación o colocación |
Clasificación de Library of Congress |
